Holen Sie sich die Stockscreener-App
0.6248
0.03%
-0.0002
Schlusskurs vom Vortag:
$0.625
Offen:
$0.6297
24-Stunden-Volumen:
152.86K
Relative Volume:
0.24
Marktkapitalisierung:
$20.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-55.92M
KGV:
-0.4431
EPS:
-1.41
Netto-Cashflow:
$-43.07M
1W Leistung:
-7.19%
1M Leistung:
-16.13%
6M Leistung:
-82.64%
1J Leistung:
-73.53%
1-Tages-Spanne:
$0.6107
$0.6499
1-Wochen-Bereich:
$0.6107
$0.6925
52-Wochen-Spanne:
$0.61
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
5.30 | 490.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
7.42 | 412.57M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
19.92 | 372.90M | 0 | 0 | 0 | 0.00 |
DWLD
Davis Select Worldwide ETF
|
43.93 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.50 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-08-15 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - The Globe and Mail
Skye Bioscience, Inc. Files Form 8-K Announcing Notice of Delisting or Failure to Satisfy Nasdaq Continued Listing Rule (March 2026) 5 - Minichart
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency By Investing.com - Investing.com India
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN
Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pio - GuruFocus
Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral By Investing.com - Investing.com Canada
Citizens reiterates Skye Bioscience stock rating on weight loss data By Investing.com - Investing.com Canada
Skye Bioscience (SKYE) Advances Nimacimab Development with Promi - GuruFocus
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Hold Rating - 富途牛牛
Skye Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
SKYE: Additive weight loss and durable efficacy drive nimacimab's advancement as a GLP-1 add-on - TradingView
Skye Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SKYE) 2026-03-10 - Seeking Alpha
Earnings call transcript: Skye Bioscience Q4 2025 highlights clinical advancements - Investing.com
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye (SKYE) Reinforces Nimacimab Strategy with Promising Data - GuruFocus
Q4 and full year results reveal momentum, Skye Bioscience, Inc. asserts - Traders Union
Skye Bioscience 2025 10-K: Net loss $(55.9M), Loss per share $(1.41) - TradingView
Skye Bioscience (NASDAQ: SKYE) highlights nimacimab obesity and metabolic pipeline - Stock Titan
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ChartMill
Skye Bioscience Q4 2025 earnings preview - MSN
A Peek at Skye Bioscience's Future Earnings - Benzinga
Skye confirms phase 2 data on nimacimab for obesity expected later this year - MSN
Growth Value: Will Skye Bioscience Inc benefit from government policyQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Market Recap: Can Skye Bioscience Inc weather a recessionEarnings Growth Summary & Risk Managed Investment Strategies - baoquankhu1.vn
Growth Report: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARVolume Spike & Low Volatility Stock Suggestions - baoquankhu1.vn
Does Skye Bioscience Inc have a competitive edgeJuly 2025 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
Smart Money: Can Skye Bioscience Inc beat the S P 5002025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Risk Report: Whats the outlook for Skye Bioscience Incs sectorJuly 2025 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
Skye Bioscience Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Aug Intraday: Is Skye Bioscience Inc in a bullish channelQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Breakout Zone: Will Skye Bioscience Inc outperform the market in YEARIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - Sahm
Why Did Skye Bioscience Stock Plummet A Whopping 60% Today? - Stocktwits
Skye Bioscience schedules March 2026 earnings release with Q4 and full-year results - Traders Union
Skye Bioscience to Release 2025 Financial Results and Business Update on March 10, 2026 - geneonline.com
Skye Bioscience : Corporate Presentation View Presentation ( 260221 Skye Corporate Presentation ) - marketscreener.com
Clinical-stage obesity biotech Skye sets March 10 results call - Stock Titan
Skye Bioscience Stock Quote, Share Price, News and Analysis - Longbridge
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Can Skye Bioscience Inc weather a recessionWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Volume Summary: Should I hold or sell FATBP nowJuly 2025 Drop Watch & Risk Managed Investment Signals - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
SKYE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SKYE Earnings History & Surprises | EPS & Revenue Results | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience says Kaitlyn Arsenault to step down as CFO effective Feb 20 - marketscreener.com
CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):